Using Nasal Lining To Breach Blood/Brain Barrier, Treatment Options Widened For Neurodegenerative And Central Nervous System Disease
Using mucosa, or the lining of the nose, researchers in the department of Otology and Laryngology at the Massachusetts Eye and Ear/Harvard Medical School and the Biomedical Engineering Department of Boston University have demonstrated what may be the first known method to permanently bypass the blood-brain barrier, thus opening the door to new treatment options for those with neurodegenerative and CNS disease. Their study is published on PLOS ONE.
Many attempts have been made to deliver drugs across the blood-brain barrier using methods such as osmotic disruption and implantation of catheters into the brain, however these methods are temporary and prone to infection and dislodgement.
"As an endoscopic skull base surgeon, I and many other researchers have helped to develop methods to reconstruct large defects between the nose and brain using the patient's own mucosa or nasal lining," said Benjamin S. Bleier, M.D., Otolaryngologist at Mass. Eye and Ear and HMS Assistant Professor.
Study co-author Xue Han, Ph.D., an assistant professor of Biomedical Engineering at Boston University, said, "The development of this model enables us to perform critical preclinical testing of novel therapies for neurological and psychiatric diseases."
Inspired by recent advances in human endoscopic transnasal skull based surgical techniques, the investigators went to work to develop an animal model of this technique and use it to evaluate transmucosal permeability for the purpose of direct drug delivery to the brain.
In this study using a mouse model, researchers describe a novel method of creating a semi-permeable window in the blood-brain barrier using purely autologous tissues to allow for higher molecular weight drug delivery to the CNS. They demonstrated for the first time that these membranes are capable of delivering molecules to the brain which are up to 1,000-times larger than those excluded by the blood-brain barrier.
"Since this is a proven surgical technique which is known to be safe and well tolerated, this data suggests that these membranes may represent the first known method to permanently bypass the blood-brain barrier using the patient's own tissue," Dr. Bleier said. "This method may open the door for the development of a variety of new therapies for neurodegenerative and CNS disease.
Future studies will be directed towards developing clinical trials to test this method in patients who have already undergone these endoscopic surgeries."
The study was supported by a grant from the Michael J. Fox Foundation for Parkinson's Research and represents a collaborative effort between Mass. Eye and Ear and Dr. Xue Han of the Biomedical Engineering Department at Boston University. Other authors include Richie E. Kohman, Rachel E. Feldman and Shrestha Ramanlal.
Massachusetts Eye and Ear Infirmary
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Massachusetts Eye and Ear Infirmary. "Using Nasal Lining To Breach Blood/Brain Barrier, Treatment Options Widened For Neurodegenerative And Central Nervous System Disease." Medical News Today. MediLexicon, Intl., 26 Apr. 2013. Web.
28 Aug. 2016. <http://www.medicalnewstoday.com/releases/259613.php>
Massachusetts Eye and Ear Infirmary. (2013, April 26). "Using Nasal Lining To Breach Blood/Brain Barrier, Treatment Options Widened For Neurodegenerative And Central Nervous System Disease." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.